QuiaPEG

Newsroom

Se nyheter från:
Page:
123456
Apr 27, 2018

QuiaPEG Pharmaceuticals Holding AB (publ), ”QuiaPEG”,announces today that the company has decided on a directed new issue of shares and subscription warrants to the Dutchinvestment group Nyenburgh Holding B.V., ”NYIP”.

Mar 12, 2018

QuiaPEG Pharmaceuticals Holding AB (publ), ”QuiaPEG”, announces today that, through its subsidiary, the company has entered into a licensing and commercialization agreement with the global Chinese company Xiamen SinoPEG Biotech Ltd, ”SinoPEG”, a key player in the pegylation industry for development , manufacturing, marketing and sales of products and services based on QuiaPEG’s release pegylation technology, Uni-Qleaver®.

Nov 30, 2016

QuiaPEG Pharmaceuticals AB (“QuiaPEG”) is to be acquired by Lucent Oil AB (“Lucent Oil”), a company listed on AktieTorget, an equities market in Stockholm, by a so called “reverse takeover”. Shareholders currently representing approximately 79.4 % of the outstanding shares in QuiaPEG (the “Shareholders”) have signed an agreement on November 28, 2016, to vote in favor of an acquisition to be made by Lucent.

Sept 12, 2016

QuiaPEG Pharmaceuticals to present at French-Swedish Life Science Day October 20, Paris, France. 


For more information, please contact Marcus Bosson, CEO, on +46 (0)70 693 1253 
or e-mail marcus.bosson@quiapeg.com or please visit: www.quiapeg.com.

Page:
123456
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message